MX2021015789A - Reduccion de la viscosidad de formulaciones farmaceuticas. - Google Patents

Reduccion de la viscosidad de formulaciones farmaceuticas.

Info

Publication number
MX2021015789A
MX2021015789A MX2021015789A MX2021015789A MX2021015789A MX 2021015789 A MX2021015789 A MX 2021015789A MX 2021015789 A MX2021015789 A MX 2021015789A MX 2021015789 A MX2021015789 A MX 2021015789A MX 2021015789 A MX2021015789 A MX 2021015789A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
reducing viscosity
viscosity
acetyl
reducing
Prior art date
Application number
MX2021015789A
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021015789(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021015789A publication Critical patent/MX2021015789A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

Se proporciona un método para reducir la viscosidad de una formulación farmacéutica que utiliza una concentración de reducción de la viscosidad de un excipiente seleccionado del grupo que consiste en la n-acetil arginina, n-acetil lisina, n-acetil prolina y mezclas de los mismos en combinación con una proteína terapéutica. También se proporciona una formulación farmacéutica estable.
MX2021015789A 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas. MX2021015789A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
MX2021015789A true MX2021015789A (es) 2022-01-27

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005243A MX2017005243A (es) 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas.
MX2021015789A MX2021015789A (es) 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005243A MX2017005243A (es) 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas.

Country Status (17)

Country Link
US (2) US11813328B2 (es)
EP (2) EP3909611B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN107206070B (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA038462B1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B1 (es)
MA (1) MA54716A (es)
MX (2) MX2017005243A (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813328B2 (en) 2014-10-23 2023-11-14 Amgen Inc. Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
EP3615069A1 (en) 2017-04-28 2020-03-04 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
PE20210779A1 (es) 2018-07-05 2021-04-21 Bayer Ag NUEVA FORMULACIOìN ESTABLE DE ALTA CONCENTRACIOìN PARA ANTICUERPOS ANTI-FXIa
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
MX2021012782A (es) * 2019-04-23 2021-11-25 Amgen Inc El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion.

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1999024063A1 (en) 1997-11-07 1999-05-20 Chiron Corporation Compositions providing for increased igf-i solubility
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
WO2001074397A1 (fr) 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
PL209928B1 (pl) 2000-11-07 2011-11-30 Novartis Vaccines & Diagnostic Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β
PT1425389E (pt) 2001-08-23 2012-02-07 Genmab As Anticorpos humanos específicos para interleucina 15 (il-15)
MXPA04008215A (es) 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008076321A1 (en) 2006-12-14 2008-06-26 Schering Corporation Engineered anti-tslp antibody
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
KR20190045414A (ko) * 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
CN104188911A (zh) * 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) * 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
MX2012005195A (es) * 2009-11-17 2012-06-12 Ipsen Pharma Sas Formulacion para combinacion de rgh y rhlgf-1.
JP6078344B2 (ja) * 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
RU2012139181A (ru) * 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
BR112014010186A2 (pt) * 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US11813328B2 (en) 2014-10-23 2023-11-14 Amgen Inc. Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
EP3763384A1 (en) 2014-12-03 2021-01-13 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
CA3038909A1 (en) 2016-09-29 2018-04-05 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
IL287947A (en) 2022-01-01
WO2016065181A1 (en) 2016-04-28
SG11201703152RA (en) 2017-05-30
ZA201702762B (en) 2022-12-21
CA2964786C (en) 2023-10-17
US20240066124A1 (en) 2024-02-29
JP7411615B2 (ja) 2024-01-11
KR20170071518A (ko) 2017-06-23
CA2964786A1 (en) 2016-04-28
AU2021200990A1 (en) 2021-03-11
IL287947B1 (en) 2024-04-01
CL2019002190A1 (es) 2019-11-22
US11813328B2 (en) 2023-11-14
EP3209332B1 (en) 2021-05-26
JP2017531682A (ja) 2017-10-26
EP3909611A1 (en) 2021-11-17
AU2015335743A1 (en) 2017-05-04
EA202191513A1 (ru) 2021-11-30
CN114569716A (zh) 2022-06-03
JP6965321B2 (ja) 2021-11-10
EA033444B1 (ru) 2019-10-31
EP3209332A1 (en) 2017-08-30
JP2022009223A (ja) 2022-01-14
MX2017005243A (es) 2017-08-18
AU2021200990B2 (en) 2023-02-16
EA201991447A1 (ru) 2019-11-29
BR112017008125A2 (pt) 2018-06-19
MA54716A (fr) 2021-11-17
CN107206070A (zh) 2017-09-26
ES2964713T3 (es) 2024-04-09
EP3909611B1 (en) 2023-08-30
BR112017008125B1 (pt) 2023-11-21
CL2017000984A1 (es) 2018-01-05
JP2020037559A (ja) 2020-03-12
KR102534017B1 (ko) 2023-05-19
IL251726A0 (en) 2017-06-29
EA201790787A1 (ru) 2017-08-31
EA038462B1 (ru) 2021-08-31
CN107206070B (zh) 2022-01-18
IL251726B (en) 2021-12-01
AU2015335743B2 (en) 2020-12-24
US20170333559A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CA2956871C (en) Compounds active towards bromodomains
MY191581A (en) Anti-pd-1 antibodies
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
CL2015002897A1 (es) Inhibidores de bace1
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
TN2014000498A1 (en) Pharmaceutical formulation
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
MX2016009464A (es) Composiciones para el uso en el tratamiento de afecciones alergicas.
MX2017017119A (es) Formulacion de alta concentracion.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12017501979A1 (en) Pharmaceutical compound
UA106905U (uk) Фармацевтична композиція